Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.
about
Practical combination therapy based on pathophysiology of type 2 diabetesMetformin and the gastrointestinal tractGut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studiesPharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetesAddition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks.Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus.Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus.Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.Diacylglycerol acyltransferase-1 (DGAT1) inhibition perturbs postprandial gut hormone release.AMPK is involved in the regulation of incretin receptors expression in pancreatic islets under a low glucose concentration.Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study.Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate CombinationSpecific inhibition of bile acid transport alters plasma lipids and GLP-1Physiology of incretins in health and disease.The role of incretin therapy at different stages of diabetes.Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study.Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes.Effects of a D-xylose preload with or without sitagliptin on gastric emptying, glucagon-like peptide-1, and postprandial glycemia in type 2 diabetes.Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with MetforminOnce-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials.Saxagliptin and metformin in fixed combination for the treatment of type 2 diabetes in adultsCombination Therapy with a Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes MellitusPharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects.Initial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptin.Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database.Sitagliptin and metformin--novel combination therapy.Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.Sitagliptin: a review.Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence.Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.Metformin + saxagliptin for type 2 diabetes.Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.Linagliptin: a review of its use in the management of type 2 diabetes mellitus.Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity.
P2860
Q28076530-1086E601-503D-4F3C-AB97-E4066BD48A28Q28079250-E0F65E4A-9F01-44A1-A386-EE5C15E62670Q28541879-AB2B7B40-450A-4177-9BB3-F5680B2FF8D4Q33566802-98B62D9A-44A5-449C-B9F1-9BCA541CDFBFQ33603409-EB39A4D3-602E-4791-8F5F-AC58A9CCDD62Q33785117-AAC8A6C6-A1FB-48C2-96DF-19AD28E87755Q33838229-4EBBB394-7F24-40D5-A0EF-8E6277BC411CQ34265490-BF4CCBC8-D8BF-47AD-B6C6-90C9AA7C7177Q34555875-5D7353B8-703E-4C02-9A9F-78FE3E4BC014Q34746178-F59F92DF-568B-4F43-A3B6-DFDAB14D3722Q34804865-226EA844-FD1B-4F26-8628-4A980E11C626Q35034772-0B3DD34A-46A1-4B28-BF80-A16C7A4E636BQ35192184-693B78DB-6F1B-42DF-B892-ED2C1E8A0676Q35703890-9D074B3E-09B4-4AE1-80BC-4553F26DC44BQ35760279-296027CD-3AAD-41A6-A773-2E45146FB1C5Q35760288-3E27EEE2-4DF5-4628-87B8-7254309B8FA5Q35772580-231F62B9-E5BA-491C-93BD-18B47DAAD981Q36674741-7CDE0997-9E9D-4115-95B3-5F4CF8FCDCF7Q36783856-72F7FAAC-3D29-4FF7-BEDF-F8AE6F41C816Q36942072-A153E53A-A283-4C74-AA5F-C079E45D61DEQ37056847-60198679-7FCB-49AC-B812-2FD9889CE423Q37059366-0249E310-C209-4BE2-81FC-D9EB9CEF9230Q37082630-E142B862-537C-48F3-B6BB-6DB811F86803Q37082917-EE666B50-8AF8-4084-958E-CA8C90C062A0Q37179450-7AAC9EA6-DA36-433F-B964-4F0BF5997B43Q37449243-4A3F805F-FCDA-42EB-990A-9A1C6A5F3E82Q37577162-66E0ECDF-909C-4268-B852-0D4BDAAC6180Q37677872-C2BC4EB1-6657-41CC-BC8B-A2F1A24C76FFQ37835284-2CA3645F-BC3F-41C3-A3E9-3DA3862D28D6Q37841554-1F7F9D2E-EFCC-4E4A-A398-F64DD373CA12Q37886184-6377DA46-42E9-4441-98F8-51932CB10FEEQ37900690-88C678C9-A59E-4326-ABF0-867D6F885ACCQ37910902-A3E5475C-11B7-4CBF-B848-D8B7898685B3Q37940632-358F5852-1D59-4144-A8CB-392038D7630CQ37965618-91C0AF1F-7585-4E12-AF7F-DAB234B8E19FQ37991385-DAB129DE-5F11-49E8-85BB-4F8B803BCB67Q38017726-1A545894-DD21-42BD-89F1-D3B16449489BQ38036742-606C3A78-D465-4DEA-9901-1224D6332B89Q38106411-911627A3-B91E-4D6D-B0CB-28AA45453601Q38122004-2A75E1D0-9C22-4AB5-9DCF-E24FF897D677
P2860
Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Dipeptidyl peptidase-4 inhibit ...... concentration of active GLP-1.
@en
Dipeptidyl peptidase-4 inhibit ...... concentration of active GLP-1.
@nl
type
label
Dipeptidyl peptidase-4 inhibit ...... concentration of active GLP-1.
@en
Dipeptidyl peptidase-4 inhibit ...... concentration of active GLP-1.
@nl
prefLabel
Dipeptidyl peptidase-4 inhibit ...... concentration of active GLP-1.
@en
Dipeptidyl peptidase-4 inhibit ...... concentration of active GLP-1.
@nl
P2093
P2860
P50
P356
P1476
Dipeptidyl peptidase-4 inhibit ...... concentration of active GLP-1.
@en
P2093
D Hilliard
D Williams-Herman
E M Migoya
J A Wagner
J Amatruda
J L Miller
P2860
P2888
P304
P356
10.1038/CLPT.2010.184
P407
P577
2010-11-03T00:00:00Z
P5875
P6179
1028418952